Health X Platform Limited Releases Q1 FY27 Earnings Call Transcript
Health X Platform Limited reported Q1 FY27 revenue of ₹440 crores, a 58% YoY increase. RetailerShakti grew 48% and SastaSundar 44% YoY. The company achieved a PAT of ₹2 crores, up from a loss in the previous quarter. Expansion into new geographies and the JITO private label initiative are key growth drivers. RetailAir product launch is planned for this quarter.
The announcement provides an update on quarterly performance and future strategy, which is material for investors. However, it's a transcript release, not a primary financial results announcement, and does not contain significant new quantitative guidance beyond revenue trends.
The company reported strong year-on-year revenue growth, improved profitability (PAT turned positive), and positive commentary on future growth drivers like geographical expansion and new initiatives. The narrowing EBITDA loss also indicates operational improvement.
Health X Platform Limited (formerly Sastasundar Ventures Limited) has released the transcript of its Earnings Conference Call for the First Quarter of Fiscal Year 2027 (Q1 FY27), held on August 11, 2026. The call, which discussed the company's performance for the quarter ended June 30, 2026, featured insights from Managing Director and CEO Mr. B.L. Mittal and CFO Mr. Lokesh Agarwal.
Mr. Mittal highlighted that Q1 FY27 marked an encouraging start to the year, with initiatives in RetailerShakti, SastaSundar, geographical expansion, and technology beginning to drive stronger revenue momentum. The company currently serves approximately 75,000 retail pharmacies with over 50,000 SKUs sourced directly from pharmaceutical companies. RetailerShakti grew 48% year-on-year, and SastaSundar grew 44% year-on-year.
The company is expanding its geographical footprint, entering Odisha, Bihar, and Jharkhand, and strengthening northern operations. Approximately 67% of RetailerShakti's business and 78% of SastaSundar's business comes from tier 2 and tier 3 markets. The new JITO private label initiative aims to make quality healthcare more affordable, with sales growing from ₹25 lakhs in Q4 FY26 to ₹79 lakhs in Q1 FY27, offering a gross margin above 50%.
Financially, revenue from operations grew over 58% year-on-year to ₹440 crores in Q1 FY27. Gross profit increased by 64% year-on-year to ₹34 crores, with gross margin improving to 7.8%. EBITDA loss narrowed to ₹15 crores from ₹20 crores in Q4 FY26. The company reported a PAT of ₹2 crores in Q1 FY27, an improvement from a loss of ₹13 crores in Q4 FY26, though lower than the ₹26 crores PAT in Q1 FY26.
Looking ahead, the company expects FY27 to be a significant year, with July revenues exceeding ₹150 crores. The focus remains on growing the platform, deepening presence, improving technology efficiency, and enhancing profitability and capital efficiency. The launch of the AI-monitored RetailAir product is scheduled for the current quarter.
What to do with a filing like this
Health X Platform Limited filed this with the NSE as a statutory disclosure, categorised under concall transcript released. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Health X Platform Limited. Read the original for the full detail.